{"analyses":[{"ciLowerLimit":"11.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.9","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","paramType":"Difference in percentage","paramValue":"17.2","statisticalMethod":"Miettinen & Nurminen method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.4","spread":"27.4","upperLimit":"36.6","value":"31.9"},{"groupId":"OG001","lowerLimit":"11.4","spread":"11.4","upperLimit":"18.4","value":"14.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"416"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"OG001","title":"Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Analysis population consisted of ITT population which included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 80 months","title":"ORR in All-comer Participants","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}